Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF)

Figures

• 

  FIGURE 1. Flowchart of the study population for calculating net clinical benefit amongst atrial fibrillation patients with non‐gender CHA2DS2‐VASc scores 0–1 after incident atrial fibrillation. AF indicates atrial fibrillation; CHA2DS2‐VASc, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke or transient ischemic attack (2 points), vascular disease, age 65–74 years, female gender category; ABCD, age ≥ 60 years, BNP level ≥ 300 pg/mL or NT‐proBNP level ≥ 300 pg/mL, creatinine clearance <50 mL/min, dimension of the left atrium ≥45 mm; BNP, B‐type natriuretic peptide; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; ATT, antithrombotic therapy; SAPT, single antiplatelet; VKA, vitamin K antagonist; NOAC, non‐vitamin K antagonist oral anticoagulant.

• 

  FIGURE 2. Kaplan–Meier curves for composite thrombotic events according to antithrombotic treatment stratified by the ABCD and non‐gender CHA2DS2‐VASc scores. Composite thrombotic events were defined as ischemic stroke, systemic embolism, and myocardial infarction. ABCD indicates Age ≥ 60 years, BNP level ≥ 300 pg/mL or NT‐proBNP level ≥ 300 pg/mL, Creatinine clearance <50 mL/min, Dimension of the left atrium ≥45 mm; CHA2DS2‐VASc, Congestive heart failure, Hypertension, Age ≥ 75 years (2 points), Diabetes mellitus, prior Stroke or transient ischemic attack (2 points), Vascular disease, Age 65–74 years, female gender category; ATT, antithrombotic therapy; SAPT, single anti‐platelet; NOAC, non‐vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist; BNP, B‐type natriuretic peptide; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.

• 

  FIGURE 3. Kaplan–Meier curves for total major bleeding events according to antithrombotic treatment stratified by the ABCD and non‐gender CHA2DS2‐VASc scores. ABCD indicates Age ≥ 60 years, BNP level ≥ 300 pg/mL or NT‐proBNP level ≥ 300 pg/mL, Creatinine clearance <50 mL/min, Dimension of the left atrium ≥45 mm; ATT, antithrombotic therapy; CHA2DS2‐VASc, Congestive heart failure, Hypertension, Age ≥ 75 years (2 points), Diabetes mellitus, prior Stroke or transient ischemic attack (2 points), Vascular disease, Age 65–74 years, female gender category; SAPT, single anti‐platelet; NOAC, non‐vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist; BNP, B‐type natriuretic peptide; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.

• 

  FIGURE 4. Net clinical benefit analyses for no antithrombotic treatment in comparison with three antithrombotic treatments according to the ABCD score, non‐gender CHA2DS2‐VASc score, and three weight models of net clinical benefit. NCB indicates net clinical benefit; CHA2DS2‐VASc, Congestive heart failure, Hypertension, Age ≥ 75 years (2 points), Diabetes mellitus, prior Stroke or transient ischemic attack (2 points), Vascular disease, Age 65–74 years, female gender category; ABCD, Age ≥ 60 years, BNP level ≥ 300 pg/mL or NT‐proBNP level ≥ 300 pg/mL, Creatinine clearance <50 mL/min, Dimension of the left atrium ≥45 mm; ATT, antithrombotic therapy; SAPT, single anti‐platelet; NOAC, non‐vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist; BNP, B‐type natriuretic peptide; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.

• 

  FIGURE 5. Net clinical benefit analyses between antithrombotic treatments according to the ABCD score, non‐gender CHA2DS2‐VASc score, and three weight models of net clinical benefit. *Net clinical benefit analyses with significant differences. NCB indicates net clinical benefit; CHA2DS2‐VASc, Congestive heart failure, Hypertension, Age ≥ 75 years (2 points), Diabetes mellitus, prior Stroke or transient ischemic attack (2 points), Vascular disease, Age 65–74 years, female gender category; ABCD, Age ≥ 60 years, BNP level ≥ 300 pg/mL or NT‐proBNP level ≥ 300 pg/mL, Creatinine clearance <50 mL/min, Dimension of the left atrium ≥45 mm; ATT, antithrombotic therapy; SAPT, single anti‐platelet; NOAC, non‐vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist; BNP, B‐type natriuretic peptide; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.